Twitter | Search | |
Dana-Farber
Dana-Farber Cancer Institute is a leading center for expert, compassionate cancer care and advanced research. Appointments at: 877-442-3324
28,280
Tweets
10,263
Following
73,620
Followers
Tweets
Dana-Farber 36m
Think like cancer to beat cancer. Take your photo at our booth 1642 at .
Reply Retweet Like
Dana-Farber 41m
Dr. Irene Ghobrial () discusses study results presented at that identified MYC aberrations and MAPK pathway mutations as risk factors for disease progression for smoldering patients. Watch here:
Reply Retweet Like
Dana-Farber 58m
Dr. Andrew Lane (), Director of our BPDCN Center, shares promising results from a of SL-401 for patients with as presented at .
Reply Retweet Like
Dana-Farber 1h
Director of Dana-Farber's Blastic Plasmacytoid Dendritic Cell Neoplasm () Center, Andrew Lane, MD, PhD, stopped by our exhibit at today! Come see us at booth #1642.
Reply Retweet Like
Dana-Farber 1h
Study shows combining with targeted drug boosts response in chronic lymphocytic :
Reply Retweet Like
Dana-Farber 4h
Dr. Robert Soiffer presents on preventing and treating relapse after allo SCT. Learn more about Dana-Farber’s transplant program at exhibit 1642.
Reply Retweet Like
Dana-Farber 17h
Low-dose treatment with interleukin-2 across multiple studies shows benefits in chronic graft-versus-host disease:
Reply Retweet Like
Dana-Farber retweeted
Adriana Perilla Glen 20h
Very proud of the work we are doing using PCROWD samples lab . Learn more here:
Reply Retweet Like
Dana-Farber 20h
Dana-Farber’s Dr. Dan DeAngelo reporting on the rapid and durable responses to Blu-285, a targeted agent for the D816V KIT mutation in patients with advanced systemic mastocytosis.
Reply Retweet Like
Dana-Farber 20h
president and Dana-Farber's Dr. Ken Anderson presents the Awards.
Reply Retweet Like
Dana-Farber 24h
Physicians at : Dr. Mark Bustoros shared results from the PCROWD study which helped identify patients with high risk smoldering . Learn how to enroll your patients with precursor conditions by visiting Dana-Farber’s exhibit, booth 1642.
Reply Retweet Like
Dana-Farber Dec 10
Today’s plenary at 2pm includes Dana-Farber’s Dr. Dan DeAngelo on Blu-285 for advanced systemic . Learn more:
Reply Retweet Like
Dana-Farber Dec 10
In Phase 1 trial, patients with advanced or aggressive form of systemic mastocytosis had rapid & durable responses with few adverse effects following treatment with investigational drug that targets genetic mutation found in more than 90% of cases.
Reply Retweet Like
Dana-Farber Dec 10
Tracking how multiple myeloma evolves by sequencing DNA in the blood:
Reply Retweet Like
Dana-Farber Dec 10
Dana-Farber study led by identifies MYK aberrations and MAPK pathway mutation as significant risk factors for disease progression for patients with smoldering . Read more:
Reply Retweet Like
Dana-Farber Dec 10
Today’s schedule includes presentations on new therapies for CLL by , Hodgkin biology by Margaret Shipp, and more. Pick up a schedule of presentations by Dana-Farber faculty at our exhibit, booth 1642.
Reply Retweet Like
Dana-Farber Dec 9
Dr. Oreofe Odejide studied the use of among patients with . Hear her presentation Sunday morning, 8:15 EST at .
Reply Retweet Like
Dana-Farber Dec 9
Tomorrow morning at , Dana-Farber’s presents on individualizing therapy for . Find out how to sequence and combine therapies for the best outcomes.
Reply Retweet Like
Dana-Farber Dec 9
Sunday at 7:30am: Head over to a presentation by Dana-Farber’s Dr. Margaret Shipp on understanding the biology of Hodgkin . Learn how the disease biology may impact prognosis and therapy.
Reply Retweet Like
Dana-Farber Dec 9
Study explores use of checkpoint inhibitors after relapse from donor transplant for hematologic :
Reply Retweet Like